Immunic (IMUX -1.6%) announces the start of dosing in a Phase 2 clinical trial, CALVID-1, evaluating IMU-838 plus standard-of-care treatment in COVID-19 patients. Topline data should be available later this year.
The company says IMU-838 is
an orally available, next-generation immune modulator that dampens the
immune response by inhibiting an enzyme called dihydroorotate
dehydrogenase (DHODH) that plays a key role in intracellular metabolism
of activated immune cells.
https://seekingalpha.com/news/3583016-dosing-underway-in-mid-stage-study-of-immunics-imuminus-838-in-covidminus-19
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.